CAR-T and CAR-NK CMC Testing Services
RCV control, cell-bank qualification, microbial safety, process-residue, and release-support testing for engineered lymphocyte products.
Program Overview
Ex vivo CAR-T and CAR-NK programs require controlled testing pathways for vector-related risk, cell-bank qualification, microbial safety, process residues, and release-facing documentation. HyQure supports engineered lymphocyte programs with RCL/RCR-related testing, cell line or cell bank characterization, microbial and adventitious-agent pathways, residual DNA-related support, and later-stage lot-release workflows.
Why HyQure - Advantages
-
RCV risk control for relevant matrices
HyQure supports RCL and RCR-related testing for matrices such as EOPC, UPB, CAR-T, or other product-appropriate materials, together with method suitability and controlled reporting. -
Cell-bank and substrate qualification
MCB, WCB, EOPC, identity, sterility, mycoplasma, adventitious-agent, retrovirus-related, and genetic-stability testing can be assembled into a release-aware qualification package. -
Microbial and process-residue support
Mycoplasma, sterility, endotoxin support, residual DNA-related workflows, and QC-support kits strengthen release-aware CMC control. -
Release-support documentation
Reports and CoA packages are framed as audit-ready and structured for sponsor quality review and phase-appropriate release decisions.
Core CAR-T / CAR-NK Testing Capabilities
-
Cell Bank CharacterizationTesting strategies for MCB, WCB, EOPC, and related cell substrates used in engineered lymphocyte workflows. -
RCL / RCR and retrovirus-related testingReplication-competent virus pathways, reverse-transcriptase-related methods, and retrovirus-related controls where relevant.
-
Microbial and adventitious-agent testingMycoplasma, sterility, endotoxin support, in vitro virus testing, and related biosafety pathways for release-relevant control.
-
Lot release and QC supportRelease-support testing,process-residue workflows,residual DNA-related support,and documentation packages for later-stage programs.
Why HyQure-Service Fit
-
Cell & Gene Therapy (CGT)
Cell and gene therapy programs requiring biosafety, cell-bank qualification, vector-risk control, microbial testing, and release-support documentation across development and manufacturing stages -
CAR-T and CAR-NK CMC Testing
Engineered lymphocyte programs requiring RCL/RCR risk control, cell-substrate and bank testing, microbial safety, process-residue support, and release-facing CMC documentation. -
In Vivo CAR Safety Testing
For in-vivo programming strategies requiring vector-biosafety assessment, replication-competent virus pathways, contaminant testing, residual nucleic-acid support, and matrix-specific biosafety investigations. -
iPSC Cell Bank Testing (GMP)
iPSC, MSC, and related cell-substrate programs requiring identity, genetic-stability, adventitious-agent, microbial, and cell-bank qualification support for regulatory-facing documentation. -
Biologics
Monoclonal antibodies, recombinant proteins, biosimilars, bispecific or trispecific antibodies, and related biologics requiring viral clearance, cell-line characterization, impurity control, microbial testing, and release support. -
ADC Characterization Testing
ADC-associated biologics programs requiring biosafety, viral clearance, production cell-line qualification, host-cell impurity support, microbial control, and release-oriented quality documentation. -
Vaccine Development
Vaccine programs requiring seed-lot or virus-bank support, adventitious-agent testing, microbial control, viral safety assessment, and release-support documentation. -
Oncolytic Virus Safety
Oncolytic-virus and related viral-therapeutic programs requiring adventitious-agent control, genetic-stability support, microbial testing, virus-testing pathways, and quality-focused release documentation. -
RNA and LNP Analytics
For RNA and LNP programs requiring raw-material biosafety, residual nucleic-acid control, microbial testing, process-residue support, and QC-focused analytical documentation within HyQure's confirmed service scope.
Product Characterization and Lot Release
Expression System
MCB, WCB, EOPC, UPB, vector-associated materials, process intermediates, and final release-support samples depending on manufacturing stage.
Required scoping
Accepted sample format, matrix, volume, and logistics requirements should be confirmed during project scoping.
Comparability Report
Testing reports, release-support summaries, method-validation documentation where applicable, and CoA-ready outputs aligned to sponsor workflows.
Related QC support
Residual DNA and HCP/HCD-related support, rapid microbiology routes, and QC kit integration may be added when technically appropriate.
Regulatory Relevance
For CAR-T and CAR-NK programs, this testing scope supports regulatory-facing documentation for engineered-cell CMC control, vector-risk management, cell-bank qualification, microbial testing, process-residue control, and release support. For broader quality context, see Quality & Compliance, Quality Management System (QMS), Regulatory Alignment & Guidelines, Certifications & Accreditations, and Data Integrity & Digital Systems.
CONNECTED CAPABILITIES
Scope Your Project
Connect with our scientific project managers to
define your analytical requirements and
timeline.
Contact Usdefine your analytical requirements and
timeline.